^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PML-RARA fusion

    i
    Other names: PML, Promyelocytic Leukemia, Tripartite Motif-Containing Protein 19, Promyelocytic Leukemia Protein, RING Finger Protein 71, Protein PML, PP8675, TRIM19, RNF71, MYL, Promyelocytic Leukemia, Inducer Of, Probable Transcription Factor PML, Tripartite Motif Protein TRIM19, PML/RARA Fusion, RARA, Retinoic Acid Receptor Alpha, Nuclear Receptor Subfamily 1 Group B Member 1, RAR-Alpha, NR1B1, Nucleophosmin-Retinoic Acid Receptor Alpha Fusion Protein NPM-RAR Long Form, Retinoic Acid Nuclear Receptor Alph
    Entrez ID:
    5914; 5371
    Related biomarkers:
    Expression
    Fusion
    Others
    Apply
    Phase III Trial in Acute Promyelocytic Leukemia Patients (APL0406) (NCT00482833)
    Phase 3
    Gruppo Italiano Malattie EMatologiche dell'Adulto
    Completed
    Last update posted :
    10/11/2022
    Initiation :
    08/01/2007
    Primary completion :
    09/01/2012
    Completion :
    10/17/2019
    PML
    |
    PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion
    |
    idarubicin hydrochloride • arsenic trioxide • mercaptopurine
    Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064) (NCT02688140)
    Phase 3
    Technische Universität Dresden
    Active, not recruiting
    Last update posted :
    08/05/2022
    Initiation :
    06/01/2016
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    PML
    |
    PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion
    |
    cytarabine • idarubicin hydrochloride • mitoxantrone • arsenic trioxide • mercaptopurine • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)